- Home
- ORGO vs CSTL Comparison
ORGO vs CSTL Comparison
Compare ORGO & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGO
- CSTL
- Stock Information
- Founded
- ORGO 1985
- CSTL 2007
- Country
- ORGO United States
- CSTL United States
- Employees
- ORGO N/A
- CSTL N/A
- Industry
- ORGO Biotechnology: Pharmaceutical Preparations
- CSTL Medical Specialities
- Sector
- ORGO Health Care
- CSTL Health Care
- Exchange
- ORGO Nasdaq
- CSTL Nasdaq
- Market Cap
- ORGO 665.8M
- CSTL 576.3M
- IPO Year
- ORGO N/A
- CSTL 2019
- Fundamental
- Price
- ORGO $4.28
- CSTL $19.78
- Analyst Decision
- ORGO Buy
- CSTL Strong Buy
- Analyst Count
- ORGO 2
- CSTL 6
- Target Price
- ORGO $5.50
- CSTL $40.00
- AVG Volume (30 Days)
- ORGO 1.3M
- CSTL 403.1K
- Earning Date
- ORGO 05-08-2025
- CSTL 05-01-2025
- Dividend Yield
- ORGO N/A
- CSTL N/A
- EPS Growth
- ORGO N/A
- CSTL N/A
- EPS
- ORGO N/A
- CSTL 0.62
- Revenue
- ORGO $482,043,000.00
- CSTL $332,069,000.00
- Revenue This Year
- ORGO N/A
- CSTL N/A
- Revenue Next Year
- ORGO $7.62
- CSTL $6.01
- P/E Ratio
- ORGO N/A
- CSTL $32.29
- Revenue Growth
- ORGO 11.29
- CSTL 51.09
- 52 Week Low
- ORGO $2.17
- CSTL $16.97
- 52 Week High
- ORGO $6.71
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- ORGO 43.72
- CSTL 36.62
- Support Level
- ORGO $4.80
- CSTL $19.22
- Resistance Level
- ORGO $5.57
- CSTL $20.30
- Average True Range (ATR)
- ORGO 0.32
- CSTL 0.81
- MACD
- ORGO -0.15
- CSTL 0.23
- Stochastic Oscillator
- ORGO 3.73
- CSTL 43.33
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME, among others. The company's test portfolio consists of test offerings to aid clinicians in the diagnosis and treatment of cancers or precancerous diagnoses in the fields of dermatology, gastroenterology, and ophthalmology and a pharmacogenomics ("PGx") test to guide optimal drug treatment for patients diagnosed with depression, anxiety, and other mental health conditions.